PCP
DNLI icon

Perbak Capital Partners’s Denali Therapeutics DNLI Stock Holding History

Perbak Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,175
Closed -$253K – 79
2026
Q1 		$253K Buy
13,175
+564
+4% +$11.2K 0.06% 272
2025
Q4 		$208K Buy
+12,611
New +$213K 0.06% 215

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perbak Capital Partners's DNLI Position: Q2 2026 in Review

Perbak Capital Partners sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 13,175 shares — an estimated $253K sold.

Perbak Capital Partners first reported a position in DNLI in Q4 2025 and held it in 2 quarters. The position peaked at $253K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Perbak Capital Partners reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 13,175 Denali Therapeutics shares in Q2 2026, an estimated $253K.
  • Perbak Capital Partners first reported a position in Denali Therapeutics in Q4 2025 and held it in 2 quarters.
  • Perbak Capital Partners's Denali Therapeutics position peaked at $253K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.